Alcon has acquired Neurotech Pharmaceuticals for $550 million, picking up the only FDA-approved treatment for a rare retinal disorder called macular telangiectasia type 2, or MacTel. The deal, announced late Tuesday, also hands Alcon the cell-therapy platform behind that drug, which the companies believe could be adapted to treat other chronic eye diseases down the line.
The acquired product, ENCELTO, is an encapsulated cell therapy surgically implanted in the eye to treat adults with MacTel Type 2, according to Alcon. The FDA approved ENCELTO under a Biologics License Application in March 2025, and the regulatory record lists the product's indication as treatment for adults with idiopathic macular telangiectasia type 2, per the FDA. Alcon may also owe additional contingent payments tied partly to commercial milestones, though the company has not disclosed specific terms, as reported by Yahoo Finance.
MacTel Type 2 is a progressive retinal disorder marked by abnormal blood-vessel development at the center of the retina, typically appearing in middle-aged adults and gradually causing blurred vision and loss of central vision. Its cause remains unknown. Alcon estimates there are about 25,000 diagnosed MacTel patients in the United States, with another 2,000 to 3,000 newly diagnosed each year, and ENCELTO is currently available only in this country.
How the Implant Works
ENCELTO continuously releases a protein called recombinant human ciliary neurotrophic factor, which can reach the retina directly after the capsule is implanted. The therapy is built on Neurotech's Encapsulated Cell Therapy platform: a small, semi-permeable capsule containing allogeneic retinal pigment epithelium cells that have been genetically engineered to produce the therapeutic protein. Ciliary neurotrophic factor is thought to trigger signaling events that help photoreceptors in the eye survive.
Clinical evidence for the therapy comes from two randomized, sham-controlled phase 3 trials that together enrolled 228 participants followed for 24 months, according to BioPharm International. Compared with sham treatment, ENCELTO reduced ellipsoid zone loss, a marker of retinal degeneration, by 54.8% in one trial and 30.6% in the other. Because Neurotech is privately held, sales figures for ENCELTO have not been publicly disclosed, the outlet notes.
A Platform Play, Not Just a Product Buy
Alcon Chief Executive David Endicott framed the acquisition as more than a single-drug purchase. “Neurotech's innovative platform sits at the intersection of cell therapy, pharmaceuticals, and surgery, making it a highly complementary addition to our current capabilities,” Endicott said in the company's announcement. The delivery technology could offer an edge over treatments for other chronic eye conditions that typically require repeat injections, the same report from the same outlet cautions.
As first detailed by MedCity News, Neurotech is based in Cumberland, Rhode Island, and ENCELTO represents its only commercial asset. Alcon, headquartered in Geneva, Switzerland, was formerly the eye-care division of Novartis before becoming a standalone company in 2019; its shares trade on both the SIX Swiss Exchange and the New York Stock Exchange.
Fits a Broader Shopping Spree
The Neurotech deal follows a string of similar bets by Alcon. In September 2025, the company paid $124 million to acquire the shares of LumiThera it did not already own, picking up Velda, a medical device for dry age-related macular degeneration. Alcon also acquired a majority stake in Aurion Biotech in 2025; that company is developing a cell therapy that could become an alternative to corneal transplants.
Those moves echo earlier acquisitions detailed by FiercePharma: Alcon paid $355 million for Novartis' Simbrinza in 2021 and $770 million for Aerie Pharmaceuticals in 2022, following the Aerie deal with a $60 million purchase of Eysuvis and Inveltys from Kala Pharmaceuticals. The pattern suggests a company steadily assembling a broader eye-disease portfolio, with the FiercePharma coverage noting the Neurotech platform could eventually serve as a launchpad for additional cell therapies targeting eye disease.
Financial Backdrop
Alcon expects the Neurotech acquisition to be modestly accretive to net sales growth in 2027 while slightly diluting core diluted earnings per share that year, before turning accretive thereafter, according to the company's own release. The deal lands against a backdrop of strong recent performance: Alcon reported first-half 2026 net sales of $5.5 billion, up 9% from the same period a year earlier, with its Surgical segment alone generating $3.0 billion, also up 9%.
That Surgical growth was led by recent equipment launches including the Unity platform, along with procedural growth and price increases in consumables, Alcon said. Implantables sales rose 3% in the first half of 2026, with intraocular lens sales up 2% on a constant-currency basis, driven largely by the PanOptix Pro lens used after cataract surgery. Alcon's Surgical business spans products for cataracts, vitreoretinal disorders, and glaucoma, giving the Neurotech platform a built-in commercial and clinical infrastructure to plug into.
